Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

New Application Note Addresses Benefits of aCGH/SNP Cancer Research Arrays

By BiotechDaily International staff writers
Posted on 10 Apr 2013
Image: CytoSure Cancer +SNP arrays from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
Image: CytoSure Cancer +SNP arrays from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
A new application note on combined array comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) arrays is now available to support researchers in navigating the combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH).

The application note, titled “Detecting copy number variants and runs of homozygosity on a single array — challenges and applications” is provided by Oxford Gene Technology (OGT; Oxfordshire, UK). aCGH has been established as the “gold-standard” platform for array-based CNV detection. Recent advances have enabled the combination of aCGH probes for CNV detection with probes able to detect SNPs. Particularly well suited for clinical genetics researchers, the application note highlights the importance and benefits of these combined probe arrays in the detection of various genetic conditions. For example, OGT’s CytoSure aCGH +SNP arrays allow any reference DNA to be used and no restriction digest of the sample is required. This enables labeling and hybridization steps to be completed in a single day (unlike typical SNP platforms) while providing information on changes in copy number and regions of homozygosity, and integrating into existing workflows.

The OGT arrays have been research-validated to provide informative, biologically relevant SNP data for various genetic aberrations such as uniparental disomy (UDP), mosaic aneuploidy and ROH, without compromising on high-quality CNV data. CytoSure aCGH +SNP arrays are available for constitutional, cancer, and molecular genetics research. Each array also comes with complimentary access to OGT’s “CytoSure Interpret Software,” a powerful, user-friendly CNV and SNP data analysis package, which contains innovative features to minimize user intervention and maximize consistency and speed of data interpretation.

Related Links:
Oxford Gene Technology
Application note


Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.